Ya Wan

Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact

Yu Tian, Chi‐Yuan Wu, Srikumar Sahasranaman, Xianbin Tian et autres

Tislelizumab, an anti-programmed cell death protein-1 monoclonal antibody, has demonstrated improved survival over the standard of care for multiple cancers. However, tislelizumab's effectiveness across different racial/ethnicity groups warrants further evaluation. This clinical pharmacology overview includes tislelizumab's pharmacokinetic properties, correlations with efficacy and …

us, cn (code pays fourni par la source)

Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach

Ahsan Rizwan, Hugh Giovinazzo, Yu Tian, Yuying Gao et autres

ABSTRACT Tislelizumab 200 mg once every 3 weeks (Q3W) is approved for the treatment of multiple cancers. We used a model‐based approach to propose three alternative dosing regimens, 150 mg Q2W, 300 mg Q4W, and 400 mg Q6W, with the aims of …

cn (code pays fourni par la source)

Alternative dosing regimens of tislelizumab proposed using modeling and simulation.

Ahsan Rizwan, Yu Tian, Yuying Gao, Kun Wang et autres

394 Background: Tislelizumab (TIS; BGB-A317) is approved for the treatment of multiple solid tumors, administered at 200 mg every 3 weeks (Q3W), and has demonstrated a flat exposure–response relationship across a wide range of doses. We evaluated alternative dosing regimens of TIS …

cn (code pays fourni par la source)

Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors

Yu Tian, Xiangyu Liu, Chi‐Yuan Wu, Zhiyu Tang et autres

Tislelizumab, an anti-programmed cell death protein 1 monoclonal antibody, has demonstrated improved survival benefits over standard of care for multiple cancer indications. We present the clinical rationale and data supporting tislelizumab dose recommendation in patients with advanced tumors. The phase I, first-in-human, …

us, cn (code pays fourni par la source)

Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors

Nageshwar R. Budha, Chi‐Yuan Wu, Zhiyu Tang, Yu Tian et autres

Tislelizumab, a humanized immunoglobulin G4 monoclonal antibody, is a programmed cell death protein 1 (PD-1) inhibitor designed to minimize Fc gamma receptor binding on macrophages to limit antibody-dependent phagocytosis, a potential mechanism of resistance to anti-PD-1 therapy. The pharmacokinetic (PK) profile of …

us, cn (code pays fourni par la source)

Enhanced Selectivity of Ultraviolet-Visible Absorption Spectroscopy with Trilinear Decomposition on Spectral pH Measurements for the Interference-Free Determination of Rutin and Isorhamnetin in Chinese Herbal Medicine

Ping-Rong Zhou, Zhang-Feng Tang, Ke-Su Wei, Ya Wan et autres

Ultraviolet-visible absorption spectrometry is used for the determination of many inorganic, organic, and biological species. However, poor selectivity limits its applications for quantitative analysis in complex mixtures. In this work, its mathematical selectivity was explored using trilinear decomposition on spectral-pH measurements for …

cn (code pays fourni par la source)

Enhanced Selectivity of Ultraviolet-Visible Absorption Spectroscopy with Trilinear Decomposition on Spectral pH Measurements for the Interference-Free Determination of Rutin and Isorhamnetin in Chinese Herbal Medicine

Ping-Rong Zhou, Zhang-Feng Tang, Ke-Su Wei, Ya Wan et autres

Ultraviolet-visible absorption spectrometry is used for the determination of many inorganic, organic, and biological species. However, poor selectivity limits its applications for quantitative analysis in complex mixtures. In this work, its mathematical selectivity was explored using trilinear decomposition on spectral-pH measurements for …